Subcutaneous interleukin-4 for relapsed non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.

被引：0
|
作者：
Kurtz, D. M. [1 ]
Tschetter, L. K. [1 ]
Allred, J. B. [1 ]
Geyer, S. M. [1 ]
Kurtin, P. J. [1 ]
Putnam, W. D. [1 ]
Rowland, K. M. [1 ]
Wiesenfeld, M. [1 ]
Soori, G. S. [1 ]
Tenglin, R. C. [1 ]
Bernath, A. M. [1 ]
Witzig, T. E. [1 ]
机构：
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2007年 / 55卷 / 02期
关键词：
D O I：
10.1097/00042871-200703010-00088
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
81
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 50 条
  • [41] Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma
    Multani, PS
    O'Day, S
    Nadler, LM
    Grossbard, ML
    CLINICAL CANCER RESEARCH, 1998, 4 (11) : 2599 - 2604
  • [42] Phase I/II trial of pamidronate and interleukin-2 (IL-2) for relapsed/refractory multiple myeloma (MM) and low-grade non-Hodgkin's lymphoma (NHL).
    Kunzmann, V
    Kelm, K
    Eckstein, S
    Wilhelm, M
    BLOOD, 2000, 96 (11) : 733A - 733A
  • [43] Phase II study of Paclitaxel plus Topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes, A
    Okpara, N
    Romaguera, JE
    Hagemeister, FB
    McLaughlin, P
    Rahman, D
    Cabanillas, F
    BLOOD, 1999, 94 (10) : 270B - 270B
  • [44] Phase II study of paclitaxel plus topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes, A
    Rahman, D
    Hagemeister, F
    Romaguera, J
    McLaughlin, P
    Cabanillas, F
    BLOOD, 1998, 92 (10) : 621A - 621A
  • [45] NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial.
    Ma, Daniel
    Galanis, Evanthia
    Schiff, David
    Wu, Wenting
    Peller, Patrick J.
    Giannini, Caterina
    Brown, Paul D.
    Uhm, Joon H.
    McGraw, Steven
    Jaeckle, Kurt A.
    Flynn, Patrick J.
    Buckner, Jan C.
    Sarkaria, Jann Nagina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma
    Lim, Soon-Thye
    Fayad, L.
    Tulpule, A.
    Modiano, M.
    Cabanillas, F.
    Laffranchi, B.
    Allievi, C.
    Bernareggi, A.
    Levine, Alexandra M.
    LEUKEMIA & LYMPHOMA, 2007, 48 (02) : 374 - 380
  • [47] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma
    Sym, Sun Jin
    Lee, Dae Ho
    Kang, Hye Jin
    Nam, Seung Hyun
    Kim, Ho Young
    Kim, Seok Jin
    Eom, Hyeon Seok
    Kim, Won Seog
    Suh, Cheolwon
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 27 - 33
  • [48] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma
    Sun Jin Sym
    Dae Ho Lee
    Hye Jin Kang
    Seung Hyun Nam
    Ho Young Kim
    Seok Jin Kim
    Hyeon Seok Eom
    Won Seog Kim
    Cheolwon Suh
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 27 - 33
  • [49] A Multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory/relapsed aggressive non-Hodgkin's lymphoma
    Sym, Sun Jin
    Kang, Hye Jin
    Nam, Seung-Hyun
    Kim, Hoyoung
    Kim, Seok Jin
    Eom, Hyeon Seok
    Kim, Won Seog
    Suh, Cheolwon
    BLOOD, 2007, 110 (11) : 1010A - 1010A
  • [50] A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma
    Blum, Kristie A.
    Baiocchi, Robert A.
    Alinari, Lapo
    Lin, Thomas S.
    Porcu, Pierluigi
    Jones, Jeffrey
    Flynn, Joseph
    Hicks, William
    Lucas, Margaret S.
    Wei, Lai
    Johnston, Jeffrey S.
    Byrd, John C.
    BLOOD, 2008, 112 (11) : 1049 - 1050
12345